Bisphosphonates Reduce Fracture Risk in Prostate Cancer Patients
Researchers found that men with metastatic prostate cancer receiving androgen deprivation therapy (ADT) had a significantly lower risk of fractures when treated with a bisphosphonate alongside standard of care (SOC).
The study, published in the Annals of Oncology journal, suggests that bisphosphonates can be an effective treatment in reducing fracture risk in these patients.
Men with metastatic prostate cancer receiving ADT had a significantly lower risk of fractures when treated with a bisphosphonate.
In a separate study, a model called PanEcho was trained on transthoracic echocardiographic (TTE) data from Yale New Haven Health System (YNHHS) between January 2016 and June 2022.
- The training data set consisted of 1.2 million echocardiographic videos.
- 32,265 TTE studies of 24,405 patients were used.
- Internal validation was performed using a temporally distinct YNHHS cohort between July to December 2022.
Author's summary: Bisphosphonates reduce fracture risk in prostate cancer patients on ADT.
More News
- LIVE: Road blocked after serious crash
- Celebration Marks Completion of Tributary Restoration at Key Klamath River Sites
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- US government shutdown continues as Senate blocks Republican-backed funding bill for 13th time
- OpenAI completes for-profit shift, gives Microsoft 27% stake
- Nag: Dam! What happened to the salmon? - Daily Emerald
- Government Shutdown Deepens: Senate Vote Fails For 13th Time As Food, Pay Crisis Loom
- 10 Facts About NVIDIA–Nokia AI-RAN Partnership and $1 bn Investment for 6G Networks - TelecomLead
- The United States Is Broke. Americans May Not Care - But the World Does - The Heartland Institute
- Saints hand keys to rookie Tyler Shough after brutal 1-7 start